Mainz Biomed Works To Ensure Early Cancer Detection W/ 90% 5 Year Survival By Improving Test Access

Benzinga 2024-06-18

Views 65

Advanced Screening Equals Early Detection: Cancer screening has to be simple, readily available, and affordable to be effective, which is where Mainz Biomed comes in. The molecular genetics diagnostic company specializing in the early detection of cancer is revolutionizing the colorectal cancer testing industry with ColoAlert, its flagship product.

Share This Video


Download

  
Report form